ArticleRenal failure2025
Association of suPAR with progression of cardiovascular calcification and cardiovascular outcomes in peritoneal dialysis patients.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Factors associated with vascular calcification in peritoneal dialysis patients: a meta-analysis.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCardiovascular calcification (CVC) is an important factor influencing cardiovascular outcomes in peritoneal dialysis (PD). We investigated the association of serum soluble urokinase plasminogen activator receptor (suPAR) with CVC progression and cardiovascular outcomes in PD patients.
methodsA total of 226 PD patients were recruited in our study. CVC assessments include abdominal aortic calcification (AAC), coronary artery calcification (CAC), and cardiac valvular calcification (ValvC). An increase in calcification score or the appearance of a new ValvC after approximately 24 months were defined as CVC progression. The endpoints were CVC progression, cardiovascular events (CVEs) and cardiovascular mortality.
resultsOf 226 PD patients, 111 had AAC, 155 had CAC and 26 had ValvC at baseline. At the end of follow-up, 41.1% of patients had AAC progression, 76.7% had CAC progression, and 6.4% had ValvC progression. Elevated serum suPAR was a significant risk factor for AAC progression and CAC progression but was no longer associated with ValvC progression by multivariate logistic regression analysis. The ROC curve showed that serum suPAR had a predictive value for CAC progression (AUC = 0.701). By multivariate Cox regression analysis, higher serum suPAR remained an independent risk factor for CVEs, but no longer an independent risk factor for cardiovascular mortality.
conclusionCVC is prevalent in PD patients. High levels of serum suPAR are associated with AAC progression and CAC progression in PD patients. Serum suPAR can be used as an independent predictor of CVEs in PD patients, but not yet for cardiovascular mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.